Left Ventricular Hypertrophy (LVH) is a risk factor for major cardiovascular diseases as stroke, myocardial infarction and sudden death, and is sustained by several hemodynamic and non-hemodynamic mechanisms. A wide spectrum of alterations in left ventricular hypertrophy geometric pattern can take the form of normal left ventricle, concentric left ventricular remodeling, concentric left ventricular hypertrophy, eccentric LVH. Hemodynamic and anatomic characteristics of LVH are represented by the alteration of coronary blood flow, endothelial dysfunction, extracellular collagen deposition and ventricular fibrosis. However, other biological phenomena such as genotype, gender, body size, environmental factors can influence left ventricular mass. The most important mechanism remains the activation of neurohormonal systems (first of all, renin-angiotensin system, secondarily catecolamines, insulin and leptin). Actual data cannot explain some LVH characteristics (LVH pattern development, LVH regression), so several open questions remain to be clarified through further investigations.
Keywords: endothelial function, nitric oxide, collagen deposition, arterial hypertension, growth hormone, ACE-inhibitor, antihypertensive therapy
The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Localisation of Endothelin-1 and its Receptors in Vascular Tissue as Seen at the Electron Microscopic Level
Current Vascular Pharmacology Meet Our Editor:
Current Cardiology Reviews Hyperuricemia: Is it a Risk Factor for Vascular Endothelial Dysfunction and Associated Cardiovascular Disorders?
Current Hypertension Reviews Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Serum Bilirubin after Acute Ischemic Stroke is Associated with Stroke Severity
Current Neurovascular Research Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets Role of PI3K/AKT, cPLA2 and ERK1/2 Signaling Pathways in Insulin Regulation of Vascular Smooth Muscle Cells Proliferation
Cardiovascular & Hematological Disorders-Drug Targets Novel Anti-Arrhythmic Drugs for Atrial Fibrillation Management
Current Vascular Pharmacology HDL Therapy for the Treatment of Cardiovascular Diseases
Current Vascular Pharmacology CXCL8 as a Potential Therapeutic Target for HIV-Associated Neurocognitive Disorders
Current Drug Targets Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine
Current Pharmaceutical Design Endothelial Dysfunction in Cardiac Allograft Vasculopathy: Potential Pharmacological Interventions
Current Vascular Pharmacology NADPH Oxidases in the Heart
Current Cardiology Reviews Statins and the Brain: More than Lipid Lowering Agents?
Current Neuropharmacology Impaired Renal Autoregulation in Susceptible Models of Renal Disease
Current Vascular Pharmacology Treating Hypertension in the Elderly: Common Problems and Solutions
Current Hypertension Reviews Changes of Expression of the Protein C Pathway Components in LPSInduced Endotoxemia–Implication for Sepsis
Cardiovascular & Hematological Disorders-Drug Targets